Carcinoma, Hepatocellular
Conditions
Keywords
Carcinoma, Hepatocellular, JNJ 42756493, a pan-Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor
Brief summary
The purpose of this study is to determine recommended Phase 2 dose \[RP2D\]) and the objective response rate of JNJ-42756493 (erdafitinib) in advanced hepatocellular carcinoma (HCC) participants with fibroblast growth factor (FGF) 19 amplification.
Detailed description
This is an open-label (all people know the identity of the intervention), multicenter (when more than one hospital or medical school team work on a medical research study), 2 parts (First, dose escalation Phase and second, dose expansion Phase) study to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical responses of JNJ-42756493 (erdafitinib) in Asian participants with advanced HCC. The duration of study will be approximately 11 months per participant. The study consists of 2 periods: Screening (28 days before study commences on Day 1); Open-label Treatment (dose escalation portion of the trial \[Part 1\]), participants are enrolled into cohorts at increasing dose levels of JNJ-42756493 (erdafitinib) in 28 day treatment cycles. Part 2, the cohort expansion part of the trial, will further explore the recommended phase 2 dose (RP2D) of JNJ-42756493 (erdafitinib) as determined in Part 1; and follow-up Phase (up to 6 months). Blood samples will be collected for evaluation of safety, pharmacokinetics, pharmacodynamics, and predictive biomarkers at pre-dose and post-dose of study treatment. Recommended Phase 2 dose (RP2D) for JNJ-42756493 (erdafitinib) will be evaluated primarily. Participants' safety will be monitored throughout the study.
Interventions
DRUGJNJ-42756493 (erdafitinib)
Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose. Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed hepatocellular carcinoma (HCC). (histology or cytology from prior tumor biopsy specimen is acceptable). For Part 1 continuous dosing regimen and Part 2, HCC participants must have fibroblast growth factor (FGF) 19 amplification based on central laboratory results * Participant must have advanced disease and meet all the following criteria: Disease progression after previous surgical or local-regional therapy, if any; Disease ineligible for surgical or local-regional therapy or systemic therapy; Received no more than 1 line of systemic therapy (Participants who are intolerant to previous systemic therapy are allowed.) * Cirrhotic status of Child-Pugh class A: Participants with Child-Pugh class B score of 7 may be considered in Part 2 if no pharmacokinetic (PK) and safety issues are identified in Part 1 from subjects with Child-Pugh class A * Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 * Participants with adequate bone marrow, liver, renal function, and electrolytes according to protocol-defined criteria within the 14 days before the first dose of study drug * Negative pregnancy test (urine or serum beta human chorionic gonadotropin \[beta (b)-hCG\]) at Screening for women of child bearing potential who are sexually active
Exclusion criteria
* Received systemic chemotherapy, targeted therapies, definitive radiotherapy, or treatment with an investigational anticancer agent within 2 weeks (in the case of nitrosoureas and mitomycin C, within 6 weeks; in the case of immunotherapy, within 4 weeks) before the first administration of study drug * Prior liver transplant * Known fibrolamellar HCC or mixed cholangiocarcinoma and HCC * Clinically active serious infections greater than (\>) Common Terminology Criteria for adverse events (AEs) grade 2 * Participants with persistent calcium or phosphate \> upper limits of normal (ULN) during screening (within 14 days prior to Day 1 of Cycle 1 up until pre-dose of Cycle 1) and despite medical management of calcium or phosphate levels
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1:Recommended Phase 2 Dose (RP2D) | Up to Part 1 Day 84 (Cycle 3, Day 28) (approximately 84 days) | RP2D will be determined based on pharmacodynamics, biomarker response or clinical response, as well as the incidence rate and nature of the toxicities observed. |
| Number of participants with Objective Response | up to Month 12 | Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC. CR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions taking as reference the Baseline sum diameters. Confirmed responses are those that persist on repeat imaging study for at least 4 weeks after initial documentation of response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | up to Month 12 | DCR defined as the proportion of participants with complete response \[CR\], partial response \[PR\], or stable disease \[SD\]), and duration of objective response (DOR). |
| Progression-free Survival | up to Month 12 | Time from date of randomization to date of first documentation of objective tumor progression or death due to any cause, whichever occurred first. |
| Maximum Observed Plasma Concentration of JNJ-42756493 (erdafitinib) | Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days) | — |
| Time of Maximum Observed Plasma Concentration of JNJ-42756493 (erdafitinib) | Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days) | — |
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days) | The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption. |
| Number of Participants With Adverse Events | up to Month 12 | An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. |
| Apparent Volume of Distribution at Steady-State of JNJ-42756493 (erdafitinib) | Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days) | — |
| Total Clearance of JNJ-42756493 (erdafitinib) | Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days) | — |
| Accumulation Index of JNJ-42756493 (erdafitinib) | Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days) | — |
| Duration of Objective Response (DOR) | Up to Month 12 | — |
| Half life of JNJ-42756493 (erdafitinib) | Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days) | — |
| Time to Progression (TTP) | up to Month 12 | Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first. |
Countries
China, South Korea, Taiwan
Outcome results
None listed